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A B S T R A C T
The natural substrates of the enzymes involved in type-II fatty acid biosynthesis (FAS-II) are acylated acyl
carrier proteins (acyl-ACPs). The state of the art method to produce acyl-ACPs involves the transfer of a
phosphopantetheine moiety from CoA to apo-ACP by E. coli holo-ACP synthase (EcACPS), yielding holo-ACP
which subsequently becomes thioesteriﬁed with free fatty acids by the E. coli acyl-ACP synthase (EcAAS).
Alternatively, acyl-ACPs can be synthesized by direct transfer of acylated phosphopantetheine moieties from
acyl-CoA to apo-ACP by means of EcACPS. The need for native substrates to characterize the FAS-II enzymes of
P. falciparum prompted us to investigate the potential and limit of the two methods to eﬃciently acylate P.
falciparum ACP (PfACP) with respect to chain length and β-modiﬁcation and in preparative amounts. The
EcAAS activity is found to be independent from the oxidation state at the β-position and accepts fatty acids as
substrates with chain lengths starting from C8 to C20, whereas EcACPS accepts very eﬃciently acyl-CoAs with
chain lengths up to C16, and with decreasing activity also longer chains (C18 to C20). Methods were developed
to synthesize and purify preparative amounts of high quality natural substrates that are fully functional for the
enzymes of the P. falciparum FAS-II system.
1. Introduction
Acyl carrier proteins (ACP) are small (~10 kDa), acidic proteins
playing a central role in the type-II fatty acid biosynthesis (FAS-II)
pathway as they shuttle the growing fatty acid chain to the enzymes
involved in the pathway. ACPs are highly conserved between various
organisms. Their structures consist exclusively of helical elements and
comprise of a DSL-motif being located in a speciﬁc loop region [1,2].
To become functional, newly expressed ACP (called apo-ACP) needs to
be activated to holo-ACP by the enzyme holo-ACP synthase (ACPS),
which transfers the phosphopantetheine moiety of Coenzyme A (CoA)
to the conserved serine residue of the DSL-motif of apo-ACP [3,4].
Together with malonyl-CoA, holo-ACP represents the starting material
for the synthesis of malonyl-ACP which in combination with acetyl-CoA
is needed for initiating fatty acid biosynthesis.
The type-II fatty acid biosynthesis system is typically found in
prokaryotic organisms and plants. In 1998, a FAS-II system was
discovered in the malaria parasite Plasmodium falciparum (P. falci-
parum) [5]. Being structurally and functionally diﬀerent from the
eukaryotic FAS-I system, it has not only generated much interest as a
putative drug target [6], but has also uncovered its role in cell
metabolism, in cell viability, and in the development of the various
stages of the complex parasite life cycle [7]. The further analysis of the
enzymes involved in parasite FAS-II with respect to their activity and
substrate speciﬁcity is therefore of high interest.
Hitherto, the thorough characterization of the P. falciparum FAS-II
pathway has been hampered by the fact that it is diﬃcult to obtain
natural acyl-ACP substrates. Traditionally, the lack of commercially
available acylated ACPs made it necessary to use acyl-CoAs as alter-
native substrates for the characterization of FAS-II enzymes of various
organisms, including FAS-II of P. falciparum. However, acyl-ACPs
should be used for an accurate determination of kinetic parameters, as
there is evidence that the FAS-II enzymes display diﬀerent behavior
with the acyl-CoA substrates [8]. Thus, an eﬃcient method for the
production of large amounts of pure and functional acyl-ACPs of all
types and chain lengths is needed for an in-depth analysis of the P.
falciparum FAS-II pathway.
The chemical methods developed to produce acyl-ACPs suﬀer from
drawbacks like polyacylation [9,10], suggesting the enzyme-directed
synthesis of acyl-ACPs as the method of choice. The archetypes and
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most widely used enzymes for the modiﬁcation of ACPs are E. coli holo-
ACP synthase (EcACPS) and E. coli acyl-ACP synthase (EcAAS), but
holo-ACP synthases of other organisms (for a comprehensive review
see [11]) and the acyl-ACP synthase of Vibrio harveyi [12,13] were
shown to be valuable alternatives.
EcACPS being promiscuous with respect to its substrates ACP and
CoA, is able to catalyze in vitro, and in presence of CoA, the conversion
of apo-ACP of a variety of organisms to holo-ACP, but can also generate
short-chain acyl-ACPs (e.g. acetyl-ACP, malonyl-ACP, and crotonoyl-
ACP) by using the corresponding acyl-CoAs and CoA analogs [11,14–
17]. The use of saturated longer chain acyl-CoAs failed in one study
[17], while it could be achieved in others [8,18–20].
Long chain acyl-ACPs are typically produced using EcAAS in a two-
step reaction. In the ﬁrst step holo-ACP is generated by EcACPS in
presence of CoA, and then EcAAS is used to attach the free fatty acids
to the terminal sulfhydryl group of the phosphopantetheine moiety of
holo-ACP. EcAAS has been shown to accept various types of fatty acids
as well as holo-ACPs of diﬀerent organisms. This method has been
applied in combination with saturated fatty acids [10,20–25], but also
unsaturated (C16:1Δ9, C18:1Δ9) [26] and β-hydroxylated fatty acid
chains [27,28]. However, the protocols usually include the detergent
Triton X-100 to stabilize EcAAS, which renders diﬃcult all downstream
assays involving the ﬁnal acyl-ACP substrates.
We along with others observed that P. falciparum ACP (PfACP)
could function as substrate for EcACPS as well as EcAAS [8,20,29–33],
and more recently also Vibrio harveyi AAS [12]. However, the full
potential of the enzyme-directed synthesis of acylated PfACPs has not
been explored yet. Thus, within the context of the biochemical
characterization of P. falciparum FAS-II enzymes using natural sub-
strates, we investigated the potential and the limits of both EcAAS and
EcACPS methods to prepare and purify preparative amounts of pure
and functional acyl-PfACP substrates using various saturated, 2-
enoylacyl-, and β-hydroxylated fatty acids (EcAAS method) as well as
acyl-CoAs (EcACPS method). Moreover, we investigated the use of
Calbiosorb resin as a new method to eliminate Triton X-100 from the
acyl-ACP solution after the EcAAS reaction.
2. Materials and methods
2.1. Materials and instrumentation
All cloning steps were performed in E. coli NovaBlue cells
(Novagen). Expression was conducted in E. coli BL21(DE3)-
CodonPlus-RIL or C41(DE3) cells (Stratagene). Sources of supplies
were as follows: pET vectors from Novagen; Pfu Turbo polymerase
from Stratagene; T4 DNA ligase and restriction enzymes from New
England Biolabs; plasmid extraction kits from Sigma; Terriﬁc Broth
medium from Difco; thrombin (T-3399) and acyl-CoAs from Sigma;
NADH and NADPH from Roche Diagnostics; Calbiosorb resin from
Calbiochem; Ni-NTA agarose from Qiagen; HiTrap Q XL and HisTrap
HP columns from Amersham Biosciences; Econo-Pac columns from
BioRad. All other supplies were reagent grade or better. An AEKTA
FPLC (Amersham Biosciences) was used for protein puriﬁcation.
Spectrophotometric measurements were carried out on a Cary 50 conc
Varian Spectrophotometer. Solutions were shaken using a Stuart see-
saw rocker (SSL-4). Proteins were analyzed by conformational sensitive
gel electrophoresis (15% CS-PAGE) [34–36] using gels routinely
containing 5 M urea and polymerized overnight, standard 10% SDS-
PAGE [37] and 10% Tris-Tricine SDS-PAGE [38]. Identity and homo-
geneity of acyl-PfACPs was conﬁrmed by MALDI-TOF-MS. Protein
concentrations were measured using the Bradford assay and BSA as a
standard [39].
2.2. Cloning, expression and puriﬁcation of proteins
The acp gene (Gene ID: 812677) sequence was PCR-ampliﬁed from
a P. falciparum 3D7 gametocyte stage cDNA pSPORT plasmid library
(kindly provided by Dr. T. Templeton, Weill Medical College of Cornell
University) using forward primer 5’-TGTGTGTGCATATGAGTACTTT-
TGATGATATTAAAAAAATTATAT-3’ and reverse primer 5’-GGAATTC-
TTATTGCTTATTATTTTTTTCTATATAAT-3’. PfACP was expressed
without its putative N-terminal signal- and translocation sequence,
resulting in a protein consisting of residues 61–137, and puriﬁed using
a similar protocol described earlier [8]. After isolation by metal chelate
aﬃnity chromatography, the N-terminal His6-tag was removed by
thrombin digestion. The protein was concentrated, diluted with
20 mM Bis-Tris (pH 6.5) to achieve a ﬁnal NaCl concentration of <
50 mM. The protein was applied to a 5 ml HiTrap Q-XL column to
separate apo-PfACP and holo-PfACP and to remove the liberated
puriﬁcation tag. A linear NaCl gradient (600 ml, ﬂow 2 ml/min) using
a buﬀer containing 20 mM Bis-Tris and 1 M NaCl (pH 6.5) was
applied. Fractions containing apo-PfACP were pooled and reapplied
to the column. Three runs were necessary to complete the separation.
The purity of apo-PfACP was veriﬁed by CS-PAGE. The pure fractions
were concentrated (Centriprep, 3 kDa MWCO) and stored at −20 °C.
The acps gene (Gene ID: 947037) was PCR-ampliﬁed from E. coli
genomic DNA using forward primer 5’-ATATACCATGGCAATATTAG-
GTTTAGGCACGGATATTG-3’ and reverse primer 5’-ATGAATTCTTAA-
CTTTCAATAATTACCGTGGCACAAGC-3’, After ligation into vector
pET30, the protein was expressed and puriﬁed using a published
protocol [8]. However, EcACPS was frozen (−20 °C) directly after metal
chelate aﬃnity chromatography, and the protein was only thawed and
desalted (PD10) into desalting buﬀer (20 mM Tris, 200 mM NaCl, 20%
glycerol, 3 mM DTT, pH 8.0) right before it was needed for the
synthesis reaction.
The E. coli aas gene (Gene ID: 947315) ligated into vector pET28
(pAasH) was a kind gift of John Shanklin (Brookhaven National
Laboratory, New York) and was applied as is for expression of EcAAS
[22]. A one liter culture of C41(DE3) cells harboring the pAasH
expression plasmid was grown over-night at 37 °C in TB, and expres-
sion was induced by addition of 0.4 mM IPTG. Six hours later, the cells
were harvested by centrifugation. For the subsequent steps it was
crucial to work with pre-cooled buﬀer solutions for washing and eluting
the protein to maintain enzyme activity. The cells were taken up in lysis
buﬀer composed of 96% buﬀer A (50 mM Tris, 20 mM MgCl2, 2%
Triton X-100, 5 mM ATP, pH 8.0) and 4% buﬀer B (50 mM Tris,
20 mM MgCl2, 500 mM imidazole, 2% Triton X-100, 5 mM ATP, pH
8.0). ATP was always added shortly before use. After adding a small
amount of DNase, the cells were disrupted by passing them twice
through a French press. The lysate was clariﬁed by centrifugation
(20 min, 4 °C, 9800 rpm), and the supernatant was applied on a Ni-
NTA column (2 ml volume) equilibrated with ice-cold lysis buﬀer. The
column was washed with 10 ml lysis buﬀer, and after an additional
wash step with a mixture of 90% buﬀer A and 10% buﬀer B, EcAAS was
eluted with 10 ml of a mixture of 40% buﬀer A and 60% buﬀer B
directly into 5 ml of ice-cold desalting buﬀer (50 mM Tris, 20 mM
MgCl2, 20% glycerol, 2% Triton X-100, 5 mM ATP, pH 8.0). The
protein was stored frozen (−20 °C) as 1 ml aliquots.
2.3. Preparation of holo-PfACP and acyl-PfACP substrates using
EcACPS
A typical acylation reaction (1 ml) consisted of 100 μM acyl-CoA for
the production of C4:0- to C12:0-PfACP or 200 μM for the production
of C14:0- to C20:0-PfACP, 250 μg of EcACPS, 1 mg apo-PfACP, 25 mM
MgCl2 in 50 mM Tris (pH 7.5). The mixture was incubated at 37 °C for
one hour. Holo-PfACP was generated applying the same conditions but
using CoA instead of acyl-CoA. EcACPS was eliminated from the
mixture by binding it to Ni-NTA agarose. To this end, a suspension
of 100 μl 5 M NaCl solution and 100 μl Ni-NTA agarose were added to
the 1 ml reaction mixture. The mixture was shaken for 5 min (30 osc/
min), and then centrifuged to eliminate the aﬃnity matrix. The
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supernatant containing acyl-PfACP was collected, and the pelleted
agarose was washed with 100 μl 50 mM Tris, (pH 7.5) to recover
remaining acyl-PfACP. The supernatant was pooled with the wash
solution, ﬁltered and concentrated (Amicon Ultra, 4.5 kDa MWCO).
Finally the substrates were desalted and exchanged into the buﬀer
needed for the enzyme assays (see section “Enzyme assays”) using
PD10 desalting columns. The eﬃcacy of the acylation reaction and the
purity of the resulting acyl-ACPs were conﬁrmed by CS-PAGE. For time
course experiments the acylation reaction was checked by taking
samples at various time points after initiation of the reaction with
EcACPS (5 s, 15 s, 30 s, 60 s, 2 min, 5 min, 10 min, 30 min and
60 min). The reaction was stopped by mixing the samples with 3-fold
concentrated CS-PAGE sample buﬀer (150 mM Tris (pH 6.8), 3.75 M
urea, 30% glycerol, 500 mM EDTA, 0.1% bromphenol blue). For all
experiments only even numbered acyl-CoAs were used.
2.4. Preparation of acyl-PfACP substrates using EcAAS
A typical acylation reaction was carried out with 10 ml of holo-
PfACP solution (prepared as described above) that was supplemented
with 2 mg EcAAS, 2.5 mM fatty acid (dissolved in toluene at 250 mM),
0.4 M LiCl, 10 mM MgCl2, 5 mM ATP, 3 mM DTT, and 2% Triton X-
100. H2O was added to give a ﬁnal volume of 15 ml. The mixture was
incubated over night at 25 °C to ensure complete conversion as judged
by CS-PAGE. In order to eliminate Triton X-100, the solution was
incubated three times with 1 ml of Calbiosorb resin in Econo-Pac
columns while agitating for 5 min (30 osc/min) each time. After three
runs, the protein was collected and concentrated (Amicon Ultra 15,
3 kDa MWCO), diluted with buﬀer C (20 mM Bis-Tris, pH 6.5) and
loaded onto a 1 ml HiTrap Q-XL column equilibrated with 90% buﬀer
C and 10% buﬀer D (20 mM Bis-Tris, 1 M NaCl, pH 6.5). The protein
was washed with 10% buﬀer D, and acyl-PfACPs were eluted using a
linear gradient of 10–30% buﬀer D (40 ml, ﬂow 2 ml/min). The eluted
acyl-PfACPs were concentrated and desalted (PD10) into the FabI
reaction buﬀer (20 mM Hepes, 150 mM NaCl, 1% DMSO, pH 7.4).
Only even numbered free fatty acids were used for the acylation
reactions. The Calbiosorb resin could be regenerated with methanol
followed by exhaustive washing with water.
2.5. Enzyme assays
The functionality of the resulting acyl-PfACPs was investigated
using three enzymes of the P. falciparum FAS-II pathway. All experi-
ments were carried out in triplicates. Control reactions were run exactly
the same way but omitting the enzyme under investigation.
PfACPs acylated with saturated fatty acids were assayed with
PfFabBF using a similar method published elsewhere [8]. The reaction
contained 30 μM malonyl-PfACP, 100 μM acyl-PfACP, 5 μg of PfFabG,
300 mMNaCl, 80 μMNADPH and 3 mMDTT in 20 mMNaH2PO4 (pH
7.5) in a total volume of 100 μl. The reaction was started with the
addition of 3 μg of PfFabBF [8], and the decrease in absorption at
340 nm was monitored for 1 min.
PfFabZ was used to test β-hydroxybutyryl-PfACP (OH-C4-PfACP).
The reaction consisted of 30 μM substrate in a mixture containing 5 μg
PfFabI, 80 μM NADH, 150 mM NaCl and 20 mM Hepes (pH 7.0) in a
total volume of 100 μl. The reaction was started with the addition of
5 μg of PfFabZ [40]. The decrease in NADH absorption was monitored
for 1 min.
Enoylacyl-PfACPs were tested with PfFabI using the same reaction
mixture as described above for β-hydroxybutyryl-PfACP (OH-C4-
PfACP), except that PfFabZ was omitted and the reaction was started
by adding 5 μg of PfFabI [41].
3. Results
3.1. Expression and puriﬁcation of proteins
Recombinant expression of PfACP typically yielded 35–45 mg of
highly pure protein as deduced from Tris-Tricine SDS-PAGE (Fig. 1,
panel A). When PfACP is expressed as described, apo- and holo-PfACP
are formed (Fig. 1, panel B, and lane 1 of panel C). Attempts to increase
the amount of apo-PfACP by varying expression temperature and using
diﬀerent growth media failed, thus apo-PfACP was separated from the
other forms by anion exchange chromatography. This was possible due
to the negatively charged phosphate group of the phosphopantetheine
moiety which caused holo- and acyl-PfACPs to elute at slightly higher
NaCl concentrations than apo-PfACP. Dimerized holo-PfACP, the
oxidized form of holo-PfACP, was found to elute at higher NaCl
Fig. 1. Expression and puriﬁcation of PfACP. (A) Tris-Tricine SDS-PAGE analysis of PfACP puriﬁcation. Lane 1, molecular weight marker; lane 2, crude extract; lane 3, insoluble
fraction; lane 4, soluble fraction; lane 5, ﬂow through of HisTrap HP column; lane 6, PfACP (11 kDa) after elution from HisTrap column; lane 7: PfACP (9 kDa) after thrombin digestion.
(B) Results of apo- and holo-PfACP separation by anion exchange chromatography using a HiTrap Q XL column. The solid line represents the elution pattern of the ﬁrst run using a
linear NaCl-gradient, yielding incompletely separated apo-PfACP and holo-PfACP. The fractions corresponding to the peak eluting between 35 and 65 ml were pooled, concentrated and
re-puriﬁed on the same column (dashed line). The fractions containing apo-PfACP were pooled again for a third run (dotted line) to achieve complete separation and pure apo-PfACP.
(C) CS-PAGE analysis of fractions eluted during the ﬁrst run of anion exchange chromatography (corresponding to solid line in panel B). Lane 1, Tris-Tricine SDS-PAGE pure PfACP (see
panel A, lane 7) before anion exchange chromatography; lane 2–10, representative samples taken from fractions corresponding to ml 45–75 of the ﬁrst run (solid line in panel B).
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concentrations than monomeric holo-PfACP, thus quantitative dimer-
ization of holo-PfACP could have a favorable eﬀect on the separation of
apo-PfACP. Subsequent attempts to increase the amount of oxidized
PfACP either failed or resulted in poor quality PfACP (data not shown).
Nevertheless, complete separation was achieved by applying a shallow
gradient (120 CVs) and three subsequent rounds of pooling and
reloading of the apo-PfACP containing fractions (Fig. 1, panel B and
C). This procedure routinely yielded around 20 mg of the desired highly
pure apo-PfACP out of one liter bacterial culture. The purity and yield
obtained are summarized in Table 1.
The puriﬁcation of EcACPS typically resulted in 30 mg of protein
per liter of culture (Fig. 2, panel A). The protein was immediately
frozen (−20 °C) after elution from the HisTrap column and only thawed
and desalted right before use. Such procedure was adopted in order to
avoid precipitation and loss of activity due to freeze-thawing in
desalting buﬀer. The His6-tag was not cleaved oﬀ as it was needed to
remove EcACPS from the acylation reaction mixture (see Section 2).
EcAAS was expressed and puriﬁed using a modiﬁed protocol of a
formerly published procedure [8,22]. With the enzyme being very
unstable and prone to deactivation upon time consuming workups, all
buﬀer solution were pre-cooled on ice and the protein was directly
eluted into the desalting buﬀer which allowed the elimination of the
desalting step. Subsequent activity tests conﬁrmed that this procedure
maintained high enzyme activity. Routinely, about 30 mg of pure and
active protein per liter of culture were yielded (Fig. 2, panel B).
3.2. Acylation of apo-PfACP by EcACPS
We found that the substrate acceptance of EcACPS is not limited to
short chain acyl-CoAs (Fig. 3, panel A), and that acyl-CoAs with chain
lengths up to 18 carbons could be used to generate the corresponding
acyl-PfACPs (Fig. 3, panel B). Under the conditions applied, the
acylation reaction was complete within 5 min when acyl-CoAs with
chain lengths up to 12 carbons were used (Fig. 3, panel C). The transfer
of the acyl-phosphopantetheine group from C14:0-CoA was less
eﬃcient, and a weak band corresponding to apo-PfACP was still
present after an incubation time of 60 min (Fig. 3, panel D). Eﬃcacy
decreased with longer chains (C16:0-CoA and C18:0-CoA) as only
about 50% of the apo-PfACP were acylated after 1 h. Nevertheless,
acylation to produce C14:0-PfACP to C18:0-PfACP could be driven to
completion within 60 min when doubling the initial acyl-CoA concen-
tration (Fig. 3, panel B, lanes 7–9). However, it was not possible to
achieve complete transfer of C20:0-CoA (Fig. 3, panel B, lane 10).
Subsequent puriﬁcation of the acyl-PfACP products did not lead to a
signiﬁcant decomposition or loss of protein.
Completeness of reaction and the purity of the acyl-PfACPs were
conﬁrmed by CS-PAGE. Interestingly, the migration of short chain
acyl-ACPs in CS-PAGE exhibited some characteristics that were speciﬁc
for the corresponding acyl-ACPs. While butyryl-PfACP (C4:0-PfACP)
usually migrated as a single band with a faint tailing (Fig. 3, panel A,
lane 2) or as single band only (Fig. 3, panel B, lane 2), the other short
chain acyl-ACPs appeared as two bands. For crotonoyl-PfACP (C4:1-
PfACP) both bands showed equal intensity (Fig. 3, panel A, lane 3),
while for malonyl-PfACP the upper band migrated with higher intensity
(Fig. 3, panel A, lane 4). For β-hydroxybutyryl-PfACP (OH-C4-PfACP)
a weak band remained at the level of the second band of the other acyl-
PfACPs, whereas the second band migrated faster as all others and with
high intensity (Fig. 3, panel A, lane 6). In contrast acetoacetyl-PfACP
seemed to migrate as a single band but with some tailing (Fig. 3, panel
A, lane 5). Interestingly, this behavior was independent of the urea
concentration in the CS-gels and could only be observed if fully (i.e.
overnight) polymerized gels were used. Subsequent mass spectrometric
analyses conﬁrmed identity and homogeneity of short chain acyl-
PfACPs (Table 2).
Regarding the longer chain acyl-PfACPs, only minor diﬀerences in
the migration pattern could be observed which did not allow distin-
guishing them by their migration front regardless of the gel composi-
tion. As a matter of fact, increasing the urea concentration improved
the resolution of apo- and holo-PfACP while it had no further inﬂuence
on the migration pattern of acyl-PfACPs with various chain lengths.
3.3. Acylation of holo-PfACP by EcAAS
The EcAAS method was able to attach saturated fatty acids starting
from C8:0 to C16:0 to holo-PfACP within 8 h, while for C18:0 and
C20:0 the reactions were not complete unless they were incubated over
Table 1
Summary of apo-ACP purification from a 1 l culture.
Purifcation step Total protein
(mg)
apo-ACP contenta
(%)
Recovery (%)
Crude extract 1200 n.d.b n.d.
HisTrap HPc 42.2 45 100
HiTrap Q XLd 1st
round
23.2 80 55
HiTrap Q XL 2nd
round
19.3 97 46
HiTrap Q XL 3rd round 18.7 100 44
a The amount of apo-ACP was estimated by SDS-PAGE and gel densitometry.
b Not determined.
c Loaded with Ni2+.
d Anionic exchange chromatography.
Fig. 2. SDS-PAGE analysis of EcACPS and EcAAS puriﬁcation. (A) Samples with respect to puriﬁcation of EcACPS were run using Tris-Tricine gels. Lane 1, molecular weight marker;
lane 2: crude extract; lane 3, insoluble fraction; lane 4, soluble fraction; lane 5, ﬂow through of HisTrap column; lane 6, puriﬁed EcACPS (22 kDa) after elution from HisTrap HP column.
(B) Samples for EcAAS puriﬁcation were run using standard SDS-PAGE. Lane 1, molecular weight marker; lane 2, crude extract; lane 3, insoluble fraction; lane 4, soluble fraction; lane
5, ﬂow through of Ni-NTA column; lane 6, puriﬁed EcAAS (81 kDa) after elution from Ni-NTA column.
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night at 25 °C. A representative example for the production of C14:0-
PfACP is given in Fig. 4 (panel A). In addition to the well documented
eﬃcacy for acylating saturated fatty acids, we found that EcAAS is also
capable of transferring unsaturated (2-enoyl) fatty acids (Fig. 4, panel
B) and β-hydroxylated fatty acids to holo-PfACP (Fig. 4, panel C), the
latter with slightly reduced eﬃciency. Amongst the 2-enoyl fatty acids
tried to attach to holo-PfACP, C4:1 (crotonic acid) was not accepted as
substrate, and C6:1 was only transferred with diﬃculty, but C8:1 to
C16:1 fatty acids were esteriﬁed to completion when incubated over-
night (Fig. 4, panel D).
The hydrophobic Calbiosorb resin was investigated as a means to
eliminate Triton X-100 from the acyl-ACP solution after the reaction.
Triton X-100 is a detergent used in the EcAAS reaction mixture to
stabilize the enzyme. Indeed, Calbiosorb treatment eﬃciently removed
the detergent while maintaining the integrity of acyl-ACPs (Fig. 4,
panel E), making it possible to skip the extensive washing step with
80% isopropanol used in the traditional method. However, some minor
loss of acyl-PfACP during workup could be observed.
3.4. Enzyme assays
The acyl-PfACPs produced by the EcAAS and the EcACPS method
were analyzed for functionality in standard activity assays. Indeed,
saturated fatty acids were readily recognized by PfFabBF (Fig. 5, panel
A), 2-enoylacyl-PfACP served as substrate for PfFabI (Fig. 5, panel B),
and OH-C4-PfACP was transformed by PfFabZ (Fig. 5, panel C).
4. Discussion
The exclusive use of natural substrates for biochemical character-
ization of FAS-II enzymes has very rarely been applied to date, which is
most likely due to the lack of commercial availability and the lack of
eﬃcient protocols to produce preparative amounts of such substrates.
However, it is more than reasonable to use native substrates to analyze
FAS-II enzymes. On the one hand, it is known that β-ketoacyl-ACP
synthases, enzymes catalyzing the synthase step in chain elongation,
only display little activity with acyl-CoAs [42,43], thus only function
with natural substrates. On the other hand, our recent work has shown
Fig. 3. CS-PAGE analysis of the apo-PfACP acylation using the EcACPS method. (A) With EcACPS short chain acyl-PfACP were obtained with high eﬃcacy. Lane 1, apo-PfACP; lane 2,
butyryl-PfACP (C4:0-PfACP); lane 3, crotonoyl-PfACP (C4:1-PfACP); lane 4, malonyl-PfACP; lane 5, acetoacetyl-PfACP; lane 6: β-hydroxybutyryl-PfACP (OH-C4-PfACP). (B)
Preparation of saturated long chain acyl-PfACPs (Cn:0-PfACP) using the EcACPS method. Lane 1, mixture of apo- and holo-PfACP used as reference; lane 2, C4:0-PfACP, lane 3, C6:0-
PfACP, lane 4, C8:0-PfACP, lane 5, C10:0-PfACP, lane 6, C12:0-PfACP, lane 7, C14:0-PfACP, lane 8, C16:0-PfACP, lane 9, C18:0-PfACP, lane 10, C20:0-PfACP. (C) Time course analysis
of acylation by EcACPS using C6:0-CoA and C14:0-CoA (D) as substrates. Up to a chain length of 12 carbons acylation is completed within 5 min. Eﬃcacy of EcACPS decreases with
longer chain acyl-PfACPs, but phosphopantetheinyl transfer can be achieved with doubled concentration of long chain acyl-CoAs.
Table 2
MALDI-TOF-MS analysis of short-chain PfACPs.
PfACP m/z [M
+H]+(expected)
m/z [M+H]+(observed)
apo-PfACP 9178.3 9178.3
holo-PfACP 9518.6 9517.9
acetoacetyl-PfACP 9602.7 9600.8
malonyl-PfACP 9604.7 9605.7
crotonoyl-PfACP (C4:1-
PfACP)
9586.7 9586.7
β-hydroxybutyryl-PfACP
(OH-C4-PfACP)
9604.7 9604.6
butyryl-PfACP (C4:0-PfACP) 9588.7 9587.9
Fig. 4. CS-PAGE analyses of holo-PfACP acylation using the EcAAS method. (A) EcAAS eﬃciently acylates fatty acids at diﬀerent oxidation states as shown for myristic acid (C14:0), (B)
2-hexadecenoic (C16:1), and (C) β-hydroxymyristic acid (OH-C14). (D) Preparation of 2-enoylacyl-PfACPs using the EcAAS method. Lane 1, holo-PfACP; lane 2, C6:1-PfACP; lane 3,
C8:1-PfACP; lane 4, C10:1-PfACP; lane 5, C12:1-PfACP; lane 6, C16:1-PfACP. (E) CS-PAGE analysis of acyl-PfACP produced by the EcAAS method and the inﬂuence of the work-up
procedures. Lane 1, holo-PfACP; lane 2, C10:1-PfACP in the reaction buﬀer after acylation; lane 3, C10:1-PfACP eluted from anion exchange column, typically yielding partially
degraded acyl-PfACP which is due to the harsh washing conditions. Lane 4, mixture of holo-PfACP and oxidized holo-PfACP as reference; lane 5, C12:1-PfACP in the reaction buﬀer after
acylation reaction; lane 6, C12:1-PfACP after ﬁnal puriﬁcation when Calbiosorb resin was used to eliminate the detergent Triton X-100.
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that kinetic parameters determined with artiﬁcial (acyl-CoA based)
substrates display diﬀerent characteristics compared to their corre-
sponding natural substrates [8]. Indeed, the unique β-ketoacyl-ACP
synthase in P. falciparum (PfFabBF) uses acyl-CoAs as substrates with
only very low activity while it readily elongates acyl-PfACPs, and it
exhibits a very diﬀerent behavior with acyl-PfACP compared to acyl-
CoAs [8]. The requirement of large quantities of natural substrates
prompted us to investigate the potential of the known methods and
production protocols based on EcAAS and the EcACPS, aiming at
ﬁnding and developing the most eﬃcient enzyme based system to
generate acylated PfACPs of high quality and at preparative amounts.
EcACPS allows the synthesis of acyl-PfACPs using acyl-CoAs with
chain lengths up to 18 carbons, but with decreasing eﬃcacy for chains
longer than 12 carbons, indicating that the relaxed substrate speciﬁcity
at the distal end of the phosphopantetheinyl moiety is disturbed with
longer chain lengths and has reached its limit with acyl chains
exceeding 18 carbons. This ﬁnding is in contrast to a recent study
showing that EcACPS can only transfer short chain CoAs to E. coli apo-
ACP [17], and it suggests that the protein-protein interactions between
EcACPS and PfACP is diﬀerent and hence in favor of long chain
phosphopantetheinyl transfer compared to E. coli apo-ACP.
Interestingly, the oxidation state of the acyl-chain attached to the
CoA does not play an important role for transfer by EcACPs as
crotonoyl-CoA, β-hydroxybutyryl-CoA and acetoacetyl-CoA are ac-
cepted as substrates. Thus, although our investigation was limited to
commercially available acyl-CoA derivatives (i.e. C4:0-CoA to C20:0-
CoA, acetoacetyl-CoA, malonyl-CoA, crotonoyl-CoA and β-hydroxybu-
tyryl-CoA), we conclude that very likely EcACPS also accepts long chain
β-hydroxyacyl-CoAs, 2-enoylacyl-CoAs and β-ketoacyl-CoAs as sub-
strates. Despite the limited availability of acyl-CoAs, their chemical or
enzymatic synthesis is well documented [44–46], and its use will
increase considerably the variety of acyl-PfACPs that can be produced
by this method. Taken together, the simple and fast reaction, combined
with the simple puriﬁcation of products, make acyl-PfACP synthesis
with EcACPS the method of choice when corresponding acyl-CoAs are
available.
The EcAAS reaction proved to be a valuable tool for the production
of longer chain acyl-ACPs when only the fatty acid form is available.
While long incubation times (8–16 h at 25 °C) are required to achieve
complete acylation of the holo-ACP, the oxidation state of the fatty acyl
chain does not inﬂuence the reaction eﬃciency, and all forms of acyl-
ACP can be obtained. Moreover, the improved EcAAS preparation led
to the robust setup of the reaction proposed in this work, and product
puriﬁcation using Calbiosorb resin signiﬁcantly avoids degradation of
the acyl-ACPs during workup. Nevertheless, a small loss of the protein
may occur, most likely due to adsorption of the acyl chain of acyl-
PfACPs to the resin.
The wide commercial availability of free fatty acids of various chain
lengths makes this method very valuable for the synthesis of acylated
PfACPs. Due to the fact that β-hydroxyacyl fatty acids are mostly sold
as racemate, the EcAAS method will produce racemic β-hydroxyacyl-
PfACPs. This may limit their use in kinetic measurements using PfFabZ
because PfFabZ, like the homologous enzymes in other organisms, is
stereoselective and only accepts the R-enantiomer as substrate [47].
However, as long as the S-enantiomer does not inﬂuence enzyme
activity, the racemic substrate can still be used for assays. The
production of longer chain β-ketoacyl-ACPs may be challenging using
the EcAAS method since β-keto fatty acids are known to be chemically
unstable, and they are, with the exception of acetoacetic acid, not
commercially available.
To overcome these issues, PfACPs acylated with saturated fatty
acids (Cn:0-PfACP), produced either using the EcAAS or the EcACPS
method, could be converted quantitatively to β-ketoacyl-PfACPs by
means of the FAS-II enzyme PfFabBF and malonyl-PfACP. If needed,
the holo-PfACP formed during the PfFabBF reaction can be separated
from the β-ketoacyl-ACP by hydrophobic chromatography [21]. The
simultaneous incubation of Cn:0-PfACP with PfFabBF and PfFabG (in
presence of malonyl-PfACP) will yield β-hydroxyacyl-PfACPs.
Remarkably, this method will furnish the preferred R-enantiomer of
the β-hydroxyacyl-PfACP produced. The production of preparative
amounts of 2-enoylacyl-ACPs out of β-hydroxyacyl-PfACPs is may be
less eﬃcient due to the fact that the PfFabZ reaction is reversible with
the reverse reaction being favored over the forward reaction [48,49],
and the resulting mixture of 2-enoylacyl-ACP and β-hydroxyacyl-
PfACP would need to be separated.
The natural substrates (acyl-PfACPs) tested in subsequent assays
were readily recognized by the corresponding enzymes (PfFabBF,
PfFabI, PfFabZ) involved in FAS-II of P. falciparum, conﬁrming that
both the EcAAS and the EcACPS method presented in this work have to
capacity to produce pure and preparative amounts of acyl-PfACPs with
full functionality in standard activity assays.
5. Conclusion
In this report we have shown that PfACP can be acylated very
eﬃciently using two enzyme based methods, and we have improved
acylation and puriﬁcation protocols which are now capable to yield
preparative amounts of a wide range of high quality natural substrates
Fig. 5. Functionality test of acylated PfACPs towards selected P. falciparum FAS-II enzymes. All substrates were fully functional and were recognized from the corresponding enzymes,
i.e. saturated acyl-PfACPs were transformed by PfFabBF (A), 2-enoylacyl-PfACPs were reduced by PfFabI (B), and β-hydroxybutyryl-PfACP (OH-C4-PfACP) served as substrate for
PfFabZ (C). The results are based on three independent experiments. Activities of PfFabBF and PfFabZ are expressed as nmol/min whereas PfFabI activity is reported as µM/s which is
due to the intrinsic high activity of this enzyme.
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that are readily recognized by the corresponding enzymes in the P.
falciparum fatty acid biosynthesis pathway. Based on the fast reaction,
simple experimental setup, combined with the straightforward puriﬁ-
cation, we propose the EcACPS method as the method of choice for the
synthesis of acyl-PfACP if the corresponding acyl-CoAs are available.
However, the EcAAS methods remains a very valuable tool if only free
fatty acids are available, and our improved protocols provide the means
to prepare them fast and at high quality. For the ﬁrst time we have the
opportunity to characterize kinetics as well as substrate speciﬁcity
without the need to use acyl-CoAs as surrogates, which will increase
our understanding of P. falciparum fatty acid biosynthesis consider-
ably.
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